<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02589626</url>
  </required_header>
  <id_info>
    <org_study_id>1245.106</org_study_id>
    <nct_id>NCT02589626</nct_id>
  </id_info>
  <brief_title>Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA</brief_title>
  <official_title>A 52-week Randomised, Double-blind, Parallel Group, Safety and Efficacy Study of Empagliflozin Once Daily as add-on Therapy to Glucagon-like Peptide-1 Receptor Agonist in Japanese Type 2 Diabetes Mellitus Patients With Insufficient Glycaemic Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This is a multi-center, randomised, double-blind, parallel-group, safety and efficacy study
      of empagliflozin as add-on to GLP-1 RA in Japanese patients with Type 2 Diabetes Mellitus
      with insufficient glycaemic control
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 29, 2015</start_date>
  <completion_date type="Actual">June 2, 2017</completion_date>
  <primary_completion_date type="Actual">June 2, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with drug-related adverse events</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>empaglifrozin 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>empagliflozin 10 mg tablet and placebo matching empagliflozin 25 mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>empagliflozin 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>empagliflozin 25 mg tablet and placebo matching empagliflozin 10 mg tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>empagliflozin 10mg</intervention_name>
    <arm_group_label>empaglifrozin 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>empagliflozin 25 mg</intervention_name>
    <arm_group_label>empagliflozin 25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>For blinding purposes</description>
    <arm_group_label>empaglifrozin 10 mg</arm_group_label>
    <arm_group_label>empagliflozin 25 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Diagnosis of type 2 diabetes mellitus

          -  Male and female patients on diet and exercise regimen who are pre-treated with
             Liraglutide at 0.9 mg/day alone for at least 10 weeks prior to screening must be
             &gt;=7.0% and &lt;=10.0% at screening

          -  Male and female patients on diet and exercise regimen who are pre-treated with
             Liraglutide at 0.9 mg/day and one of oral antidiabetic drug (OAD) for at least 10
             weeks prior to Visit 1 must be &gt;=7.0% and &lt;=9.0% at screening and &gt;=7.0% and &lt;=10.0%
             at placebo run-in

          -  Male and female patients on diet and exercise regimen who are pre-treated with OAD
             alone for at least 10 weeks prior to Visit 1 must be &gt;=7.0% and &lt;=10.0% at both
             screening and placebo run-in

          -  Age at informed consent must be &gt;=20 years

          -  BMI at screening must be &lt;=40 kg/m2

          -  Further inclusion criteria apply

        Exclusion criteria:

          -  Uncontrolled hyperglycaemia with a glucose values &gt;270 mg/dL (&gt;15.0 mmol/L) after an
             overnight fast during switch/washout/placebo run-in period and confirmed by a second
             measurement

          -  Patients who are drug-na√Øve at screening visit or treat with any of insulin,
             thiazolidine dione, SGLT-2 inhibitor within 10 weeks prior to informed consent.

          -  Acute coronary syndrome, stroke or transient ischemic attack within 12 weeks prior to
             informed consent

          -  Indication of liver disease, defined by serum levels of either alanine
             aminotransferase, aspartate aminotransferase, or alkaline phosphatase above 3 x upper
             limit of normal as determined during screening and/or switch/washout/placebo run-in
             period

          -  Impaired renal function, defined as eGFR &lt;45 mL/min/1.73m2 (Japanese equation) as
             determined during screening and/or switch/washout/placebo run-in period

          -  Further exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1245.106.81011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukuoka, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.106.81001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukushima, Koriyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.106.81010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hiroshima, Fukuyama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.106.81005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ibaraki, Naka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.106.81007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kanagawa, Kawasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.106.81016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kanagawa, Yamato-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.106.81015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kanagawa, Yokohama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.106.81008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mie, Yokkaichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.106.81012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Kashiwara-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.106.81013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.106.81009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Suita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.106.81003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Chuo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.106.81006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Chuo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.106.81014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Hachioji-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.106.81002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Shinjuku-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.106.81004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Shinjuku-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2015</study_first_submitted>
  <study_first_submitted_qc>October 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2015</study_first_posted>
  <last_update_submitted>June 29, 2017</last_update_submitted>
  <last_update_submitted_qc>June 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

